In today's Washington Post, regulatory policy columnist Cindy Skrzycki has a piece on FDA user-fees — money pharmaceutical companies pay so that FDA can conduct safety studies on specific drugs. The column discusses the upcoming reauthorization of the Prescription Drug User Fee Act, as well as FDA's growing penchant for using industry money to fund agency activities. Check it out here.